Previous Article | Next Article ![]()
Molecular and Cellular Biology, January 2001, p. 109-125, Vol. 21, No. 1
SFB Biomembrane Research Center, Department
of Biochemistry, Technical University Graz, A8010 Graz,
Austria1; Division of Life Sciences,
Bureau of Biological Research, Rutgers University, Piscataway, New
Jersey 08854-80822; and Department of
Biochemistry, Uniformed Services University of the Health Sciences,
Bethesda, Maryland 208143
Received 8 August 2000/Returned for modification 13 September
2000/Accepted 3 October 2000
The TSC13/YDL015c gene was identified in a screen for
suppressors of the calcium sensitivity of csg2 The sphingolipids are essential
components of eukaryotic cells that have been implicated in a large
number of cellular processes, including signaling, secretion,
Ca2+ homeostasis, and heat stress response
(46). Sphingolipids consist of ceramide linked through
either a glucosyl or phosphodiester bond to a polar head group. The
ceramide moiety is comprised of a fatty acid joined in amide linkage to
a long-chain base (LCB). In Saccharomyces cerevisiae, the
fatty acid is a hydroxylated C26 very long chain fatty acid
(VLCFA), the LCB is usually phytosphingosine, and the polar head group
is an inositolphosphoryl moiety that can be further decorated by
mannosylation and a second inositolphosphorylation (Fig.
1; for a
review, see reference 13). The importance of the
VLCFAs is highlighted by the observation that mutants unable to
synthesize LCBs are inviable, but growth can be restored by second-site
mutations in the SLC1 gene that result in the synthesis of a
novel class of VLCFA-containing inositolglycerophospholipids (36), which structurally mimic sphingolipids.
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.1.109-125.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Tsc13p Is Required for Fatty Acid Elongation and
Localizes to a Novel Structure at the Nuclear-Vacuolar Interface in
Saccharomyces cerevisiae
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
mutants
that are defective in sphingolipid synthesis. The fatty acid moiety of
sphingolipids in Saccharomyces cerevisiae is a very long
chain fatty acid (VLCFA) that is synthesized by a microsomal enzyme
system that lengthens the palmitate produced by cytosolic fatty acid
synthase by two carbon units in each cycle of elongation. The
TSC13 gene encodes a protein required for elongation,
possibly the enoyl reductase that catalyzes the last step in each cycle
of elongation. The tsc13 mutant accumulates high levels of
long-chain bases as well as ceramides that harbor fatty acids with
chain lengths shorter than 26 carbons. These phenotypes are exacerbated
by the deletion of either the ELO2 or ELO3
gene, both of which have previously been shown to be required for VLCFA
synthesis. Compromising the synthesis of malonyl coenzyme A
(malonyl-CoA) by inactivating acetyl-CoA carboxylase in a
tsc13 mutant is lethal, further supporting a role of Tsc13p
in VLCFA synthesis. Tsc13p coimmunoprecipitates with Elo2p and Elo3p,
suggesting that the elongating proteins are organized in a complex.
Tsc13p localizes to the endoplasmic reticulum and is highly enriched in
a novel structure marking nuclear-vacuolar junctions.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

View larger version (33K):
[in a new window]
FIG. 1.
Pathways of fatty acid elongation, LCB, and sphingolipid
synthesis in S. cerevisiae. Palmitoyl-CoA is synthesized
from acetyl-CoA and malonyl-CoA by soluble FAS. Palmitoyl-CoA is
elongated to a C26 VLCFA by a membrane-associated fatty
acid elongating system (A, left branch). Each cycle of elongation
requires four successive reactions and lengthens the growing fatty acid
by two carbon units; condensation of malonyl-CoA with the acyl-CoA substrate, reduction of the
3-ketoacyl-CoA, dehydration of the 3-hydroxyacyl-CoA, and reduction of
the trans-2,3-acyl-CoA. Although the intermediates and the
product of the elongation cycle are shown as CoA derivatives, this has
not yet been experimentally confirmed. The organization of the
elongating enzymes with respect to each other is unknown. The LCBs are
synthesized by the pathway shown in the right branch of panel A; the
pathway for the conversion of ceramide to mature sphingolipids is shown
in panel B.
The majority of cellular long-chain fatty acids have 16 or 18 carbons
and are synthesized by the soluble fatty acid synthase (FAS) complex
that is comprised of two multifunctional subunits encoded by the
FAS2 (
-subunit) and FAS1 (
-subunit) genes
(28, 52, 53, 65). While the bulk of the cellular fatty
acids are synthesized by FAS, the VLCFAs are synthesized by
membrane-associated fatty acid elongating systems. Although fatty acid
elongation has been extensively assayed in microsomal fractions from
mammalian cells, the component enzymes have resisted purification, and
until recently none of the genes encoding the enzymes had been
identified (reviewed in reference 7). The elongating
systems catalyze four reactions, lengthening the fatty acid by two
carbons in each cycle of elongation (Fig. 1). Malonyl coenzyme A
(malonyl-CoA), synthesized by acetyl-CoA carboxylase (ACC), provides
the 2-carbon unit both for de novo long-chain fatty acid synthesis by
FAS and for elongation of the long-chain fatty acids to the VLCFAs
(Fig. 1). In contrast to acc1 null mutants
(21), strains defective in the FAS1 or
FAS2 gene can be rescued by supplementation of the growth
medium with long-chain fatty acids (44). This indicates that malonyl-CoA is required for an essential process other than de
novo long-chain fatty acid synthesis, most likely the elongation of the
long-chain fatty acids to the VLCFAs. Conditional mutations of
acc1 result in severe membrane phenotypes at the nuclear
envelope-nuclear pore complex under restrictive conditions
(48) and also affect vacuolar membrane morphology and
inheritance, possibly through altered fatty acylation of the vacuolar
membrane protein Vac8p (47).
Despite the ubiquitous presence of VLCFAs and the evidence that they
are essential for viability, little is known about the precise roles of
the VLCFAs or about the molecular nature of the fatty acid elongating
enzymes. Candidates for yeast cells defective in the elongating system
were identified in two independent screens. These screens took
advantage of the observation that fas2 mutants will grow in
medium supplemented with myristate (C14) as long as this
fatty acid can be converted to the long-chain (C16 and C18) and very long chain (typically C26) fatty
acids by the elongating systems. An additional mutation in the
fas2 background rendering cells unable to grow on myristate
but able to grow on palmitate (C16) identified the
ELO1 gene (14, 59). Subsequently, Elo1p was
demonstrated to be required for efficient elongation of myristate to
palmitate. The ELO1 gene has two structural and functional homologs in S. cerevisiae, FEN1/ELO2 and
SUR4/ELO3. Elo2p is involved in elongation of fatty acids up
to C22 and C24, while Elo3p has a broader
substrate specificity and is required for conversion of C24
to C26 (37). Neither Elo2p nor Elo3p confers
essential functions by itself; however, elo2
elo3
double mutants are inviable (37).
The yeast ELO3/SUR4 and/or ELO2/FEN1 genes have also been identified in a number of other genetic screens (17, 19, 56), including one for suppressors of the Rvs (reduced viability upon starvation) phenotype of cells lacking the RVS161 gene (12). Rvs161p is homologous to amphiphysin, a vesicle-associated protein that participates in endocytosis in mammalian cells (10, 57, 58), and a mutant allele of rvs161 was recovered in a screen for endocytic mutants in S. cerevisiae (35). Interestingly, inactivation of the ELO2 or ELO3 gene also bypasses the requirement for Snc V-SNAREs, further suggesting a role for VLCFAs in membrane trafficking (11).
VLCFAs are predominantly present in sphingolipids and the
phosphatidylinositol (PtdIns) moiety of
glucosylphosphatidylinositol (GPI)-anchored proteins. Sphingolipids
in yeast are assembled in the endoplasmic reticulum (ER) and then
modified and matured in the Golgi; they are major lipid constituents of
the plasma membrane (22). The csg1 and
csg2 mutants are defective in sphingolipid synthesis at the
step of inositolphosphorylceramide (IPC) mannosylation (Fig. 1); they
therefore accumulate high levels of IPC, which is correlated with
sensitivity to 10 mM Ca2+ in the growth medium (3,
68). Many mutations that suppress the Ca2+
sensitivity of the csg2 mutant cells reside in genes
required for IPC synthesis (15). Interestingly, mutations
that suppress the multiple phenotypes of the rvs161
mutant (named sur mutants) (12, 43, 56)
identify genes that overlap extensively with the collection of
sphingolipid synthesis mutants that were identified as suppressors of
the csg2 Ca2+ sensitivity. The SUR1
gene is allelic to CSG1 (3). The
SUR2 gene encodes the hydroxylase that converts
dihydrosphingosine to phytosphingosine; therefore, sur2
mutants synthesize ceramides and sphingolipids with dihydrosphingosine
rather than phytosphingosine as the LCB (20) (Fig. 1). The
sur4/elo3 mutant is deficient in sphingolipid synthesis
because it makes reduced levels of VLCFA (11, 14, 37, 59).
We identified both the SUR4/ELO3 and FEN1/ELO2
genes in the csg2 suppressor screen because null mutations in either gene reduce IPC accumulation and thereby reverse
Ca2+ sensitivity of the csg2
mutant. This
observation suggested that other genes required for fatty acid
elongation might be identified in our suppressor collection.
In this report, we identify and characterize the TSC13 gene and provide evidence that it encodes the enoyl reductase component of the elongating system required for the synthesis of VLCFAs. Tsc13p interacts physically and genetically with other components of the elongation machinery and is localized in the ER but is highly enriched at the interface between the nucleus and the vacuole, marking a novel subdomain of the ER, the nuclear-vacuolar junction.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Media, strains, and genetic manipulations.
The yeast strains
used in this study are listed in Table
1. Yeast
media were prepared and cells were grown according to standard procedures (54).
|
Cloning and disruption of the TSC13 gene.
The
wild-type TSC13 gene was cloned from a YCp50-based genomic
library (45) based on its ability to complement the ts
(temperature-sensitive) phenotype of TDY2050 (tsc13-1
csg2::LEU2) (2). Two plasmids that conferred temperature resistance were recovered, and sequence analysis showed that they shared a segment of chromosome IV containing YDL015c and YDL016c. A 1,500-bp NotI and
SalI-ended PCR fragment containing only the YDL015c open
reading frame with 370 bp of upstream and 205 bp of downstream flanking
sequence was generated using primers 12200 and 12201 (Table
2). The fragment was cloned into pRS316
(55), and the resulting plasmid (pTSC13-316) was found to
complement the ts phenotype of TDY2050. A disrupting allele of
YDL015c/TSC13 was constructed by placing an
EcoRI-ended PCR fragment carrying the
TRP1-selectable marker between the MunI (located
42 bp upstream of the start codon) and EcoRI (located in
codon 72) sites of YDL015c.
|
Epitope tagging of Tsc13p, Elo2p, and Elo3p. A three-copy Myc epitope (Myc3) was introduced at the amino terminus of Tsc13p. To accomplish the tagging, an AvrII site was first introduced after the start codon of TSC13 on plasmid pTSC13-316 by QuikChange mutagenesis (Stratagene, La Jolla, Calif.), using the complementary mutagenic primers 12449 and 12450 (Table 2). A SpeI-ended fragment carrying the Myc3 cassette was generated by PCR using a Bluescript-based Myc3-containing plasmid (gift of Dan TerBush, Department of Biochemistry, Uniformed Services University of the Health Sciences) and ligated into the AvrII site. The NotI-to-XhoI fragment carrying the Myc-tagged TSC13 allele was ligated into pRS426 to generate the MYC-TSC13-426 plasmid. This Myc-tagged TSC13 allele complemented the temperature sensitivity of the tsc13 mutant, demonstrating that it is functional.
The hemagglutinin epitope (HA)-tagged Elo3p and HA-tagged Elo2p constructs were made by inserting SalI-ended restriction fragments extending from the start codon of Elo2p (or Elo3p) to a site 128 bp (for ELO2) or 1,115 bps (for ELO3) downstream of the stop codon into the SalI site of plasmid pADH-HA. The SalI fragments were generated using the PCR primers listed in Table 2 with vector pCRELO2 (37) as template for ELO2 and strain DTY10A (Table 1) genomic DNA for ELO3. The resulting plasmids, pADH-HA-ELO2 and pADH-HA-ELO3, contained the full-length ELO genes with an HA tag fused at the amino terminus, under control of the ADH1 promoter. The HA-tagged Elo2p and Elo3p restored normal VLCFA synthesis to the elo2 and elo3 mutants, respectively.Disrupting the ELO2 and ELO3 genes. A BamHI-ended PCR fragment extending from 280 bp upstream of the start codon of ELO3 to 180 bp past the stop codon was generated using primers 9041 and 9042 (Table 2) and ligated into pUC19. The resulting plasmid was digested with MscI to release a 140-bp fragment (encoding codons 45 to 91 of ELO3), and an XhoI linker was ligated in at the deletion junction. A SalI-ended TRP1 fragment was ligated into the XhoI site to generate the disrupting allele, which was liberated from plasmid pUC19 by digestion with KpnI and SalI. For the ELO2 gene, a BamHI-ended PCR fragment extending from 160 bp upstream of the start codon to 170 bp past the stop codon was generated using primers 9043 and 9044 (Table 2) and ligated into pUC19. An EcoRI-ended TRP1 fragment was ligated between the MunI sites of ELO2, thereby replacing codons 92 to 183 with the selectable marker. The disrupting allele was liberated from the plasmid by digestion with KpnI and SalI.
Ceramide and LCB analysis. Ceramides were extracted and analyzed by thin-layer chromatography (TLC) as previously described (20). LCBs were extracted, separated by TLC, and visualized using ninhydrin as described elsewhere (2).
Fatty acid analysis.
Cells (5 × 108) in
mid-logarithmic-stage growth were harvested and resuspended in 100 µl
of distilled H2O along with 25 µg of linoleic acid (18:2)
as an internal standard for extraction of the fatty acids. Fatty acid
methyl esters were prepared by HCl methanolysis as previously described
(59), resuspended in 50 µl of hexane, and stored at
20°C. Gas chromatography (GC) was performed using a Varian 3400CX
chromatograph and a Supelcowax TM10 column, and data were collected and
analyzed using Class-VP Chromatography Data System version 4.1 software
(Shimadzu Scientific Instruments) as described elsewhere
(6).
Elongase assays.
Microsomes were prepared from the wild-type
or tsc13-1 mutant cells as previously described
(18). By using the purified microsomes for the elongation
assays, the background of acyl-CoA-independent incorporation of
malonyl-CoA into fatty acids (as a result of the soluble FAS activity)
was reduced to less than 10% of the acyl-CoA-dependent incorporation
of malonyl-CoA into fatty acids. Total elongase activity was measured
in a volume of 200 µl containing 50 mM Tris (pH 7.5), 1 mM
MgCl2, 150 µM Triton X-100, 1 mM NADPH, 1 mM NADH, 10 mM
-mercaptoethanol, 40 µM acyl-CoA acceptor (either palmitoyl-CoA,
stearoyl-CoA, or eicosanoyl-CoA), and 60 µM
[2-14C]malonyl-CoA (0.05 µCi/ml) at 37°C. The
reaction was initiated by the addition of 0.3 to 1.0 mg of microsomal
protein. Protein concentrations were determined using the Bio-Rad
protein assay reagent (Bio-Rad Laboratories, Hercules, Calif.). For
assays of only the condensing activity, the NADPH and NADH were
omitted. At various times, the reaction was terminated by adding 200 µl of 5 M KOH-10% methanol MeOH and heating at 80°C for 1 h.
Following addition of 200 µl of 10 N H2SO4,
fatty acids were recovered by two 1.5-ml extractions into hexane. The
extracted fatty acids were resolved by silica gel TLC using
hexane-diethyl ether-acetic acid (30:70:1) as the developing solvent.
The radiolabeled fatty acids were detected and quantified using a
PhosphorImager SI (Molecular Dynamics, Inc., Sunnyvale, Calif.).
Immunoprecipitation. Microsomes were prepared from strains containing Tsc13p-Myc and either Elo2p-HA or Elo3p-HA as previously described (18). The microsomes were solubilized at 1 mg/ml with 2 mM sucrose monolaurate (Roche Diagnostics, Indianapolis, Ind.) for 10 min, and the high-speed (105 × g, 30 min) supernatant was collected. The supernatant (150 µl) was incubated with 3 µl of the precipitating antibody for 2 h and then with 20 µl of protein A-Sepharose (125 mg/ml; Sigma) for 2 h. The precipitates were washed three times with 600 µl of 50 mM HEPES (pH 7.5) and resuspended in 150 µl of sodium dodecyl sulfate (SDS) loading buffer; a 10-µl sample was subjected to SDS-polyacrylamide gel electrophoresis (PAGE) on an 8% gel. Following transfer of the separated proteins to nitrocellulose, the blots were blocked in 0.1 M Tris (pH 7.5)-0.15 M NaCl-0.1% Tween 20-5% dry milk. Tsc13p-Myc was detected with horseradish peroxidase (HRP)-conjugated monoclonal anti-Myc antibodies (from InVitrogen) at 1/5,000. Elo2p-HA and Elo3p-HA were detected using HRP-conjugated monoclonal anti-HA antibodies (from Boehringer Mannheim) at 1/1,000. The bound antibodies were detected by the ECL Western blotting detection system (Amersham Pharmacia Biotech).
Construction of Tsc13p-GFP by chromosomal fusion.
Plasmid
pMK199-GA5-yEGFP-kanMX6 containing a five-copy glycine-alanine (GA5)
linker fused to yeast enhanced green fluorescent protein (yEGFP) and
the kanMX6 resistance marker, was used as the template for PCRs to
amplify the integration cassette (64). Using the two
primers pYDL015cGA5
and pYDL015cMX6
(Table 3) a 2,550-bp fragment was
generated by PCR. The upstream primer contained 30 nucleotides
homologous to the GA5 linker 5' to the yEGFP sequence of the template
plasmid and 46 nucleotides corresponding to the 3' end of the YDL015c
coding sequence (excluding the stop codon). The downstream primer
contained 26 nucleotides homologous to the kanMX6 sequence and 47 nucleotides homologous to the chromosomal sequence downstream of the
YDL015c reading frame. PCR amplification was performed in a 25-µl
standard reaction mix containing 1× Ex-Taq buffer (as specified by the
supplier [Boehringer, Mannheim, Germany]), 300 ng of plasmid DNA, 100 pmol of each primer per µl, and 2.5 mM deoxynucleoside triphosphates. After the initial denaturation step at 94°C for 5 min, the PCR was
started by the addition of 2 U of Takara Ex-Taq polymerase (Boehringer). The fragment was amplified during eight cycles of 30 s at 94°C, 30 s at 54°C, and 150 s at 72°C, 25 cycles
of 30 s at 94°C and 180 s at 72°C, and a final elongation
step of 12 min at 72°C. The resulting PCR fragment was purified by
using a QIAquick PCR purification kit (Qiagen). About 0.5 to 1 µg of the PCR product was used for yeast transformation into diploid wild-type strain FY1679, and transformants were selected on plates containing Geneticin (G418; 200 µg/ml; Calbiochem). After restreaking on G418 plates, positive transformants were verified by colony PCR
using the primers pYDL015c
, kanMX
, and
pGFP4
(Table 3). Growth tests verified that the
C-terminal chromosomal fusion of TSC13 with green
fluorescent protein (GFP) rendered cells fully viable and
phenotypically indistinguishable from wild-type cells.
|
Construction of Opi3p-GFP by chromosomal fusion.
The
Opi3p-GFP (a bona fide ER protein;
phospholipid-N-methyltransferase 24)
chromosomal fusion was constructed and verified as described above for
Tsc13p-GFP, using the primer pairs listed in Table 3. PCR products were
transformed into the diploid wild-type strain FY1679, and transformants
were selected on YPD plates containing Geneticin (200 µg/ml). After
restreaking on G418 plates, positive transformants were verified by
colony PCR using the primers pOP13
,
kanMX
, and pGFP4
(Table 3).
Construction of Elo2p-GFP. The GFP-fused Elo2p construct was made by inserting the SalI-flanked restriction fragment containing ELO2 (described above) into the SalI site of vector pGAL1-GFP. The resulting plasmid encoded a chimeric protein consisting of a GFP domain fused in frame to the amino terminus of the full-length Elo2 protein. The GFP-Elo2p fusion repaired the altered VLCFA phenotype associated with the elo2 mutant.
Fluorescence microscopy. Microscopy was performed on a Leica TCS 4d confocal microscope equipped with an Ar-Kr laser, an acousto-optical tunable filter for laser wavelength selection and attenuation, a 500-nm beam splitter/dichroic mirror, and a 525/50-nm band-pass filter for GFP detection. For double-labeling experiments with the vacuolar dye FM4-64 [N](3-triethylammoniumpropyl)-4-(p-diethylaminophenylhexatrienyl)] pyridinium dibromide Molecular Probes, Eugene, Oreg.), an additional dichroic 525-nm beam splitter was used in the emission path, and 525/50-nm band-pass and 590-nm long-pass filters were used for simultaneous GFP and FM4-64 detection, respectively. The objective was a 100×/1.4-numerical-aperture lens, and transmission was recorded using differential interference contrast (DIC; Nomarski) optics. Images were routinely acquired using 4-8 × line averaging mode (ScanWare; Leica Microsystems). Cells were stained with FM4-64 (Molecular Probes) (63) and immobilized for microscopic inspection as described elsewhere (26). Images were edited using Adobe Photoshop 5.0 and NIH Image 1.62.
| |
RESULTS |
|---|
|
|
|---|
Isolation of the tsc13 mutants and cloning of the
TSC13 gene.
The csg2
mutant fails to
mannosylate IPC and consequently accumulates high levels of IPC
(3, 68). These lipid alterations result in a
Ca2+-sensitive phenotype; therefore, suppressor mutants
that are able to grow on Ca2+ identify genes required for
IPC synthesis. Twenty-one TSC complementation groups were
identified in a screen for mutants that had acquired a single mutation
that conferred both suppression of Ca2+ sensitivity and
temperature sensitivity (2). Genetic linkage analysis
demonstrated that in most cases both phenotypes were caused by the same
mutation. Three independent mutations in the TSC13 gene were
identified in this screen. The TDY2050 mutant, containing the
tsc13-1 allele, was chosen for further analysis and was
found to have phenotypes (Fig. 2) similar
to those observed in mutants lacking either the ELO2 or
ELO3 gene. As shown in Fig. 2, disruption of either the
ELO2 or the ELO3 gene also suppressed the
Ca2+-sensitive phenotype of the csg2
mutant
grown to an optical density at 600 nm (OD600) of 0.1 on SD
minimal medium. On rich (YPD) medium, the elo3 csg2 double
mutant grew poorly at 37°C and failed to grow at 26°C. The ts
phenotype caused by the tsc13-1 mutation was more severe in
strains lacking the CSG2 gene (Fig. 2). Furthermore, disruption of either the ELO2 or ELO3 gene
exacerbated the ts phenotype caused by the tsc13-1 mutation
(Fig. 2). The genetic interactions between tsc13 and
elo2 and with elo3 suggested that Tsc13p might be
required for VLCFA synthesis and function in the same pathway as Elo2p
and Elo3p.
|
Tsc13p is evolutionarily conserved and has similarity to a steroid
reductase.
The TSC13 gene is predicted to encode a
protein of 310 amino acids with significant homology (35% identity,
50% similarity) over its entire length to evolutionarily conserved
proteins of previously unknown function called the SC2 proteins (Fig.
3a). The SC2 gene, originally
identified in a screen for cDNAs that encode rat synaptic
glycoproteins, was found to be expressed at high levels in the brain
and at lower levels in other tissues (23). The pattern of
hydrophobicity and the positions of potential membrane-spanning domains
in the Tsc13p/SC2 proteins have been conserved throughout evolution
(Fig. 3b), and Tsc13p behaves as an integral membrane protein
(discussed below). As previously noted (23) for the SC2
protein, Tsc13p has homology in the carboxy-terminal 150 amino acids
(29% identical, 45% similar) to steroid-5-
-reductase, which
catalyzes the reduction of testosterone to dihydrotestosterone. Steroid-5-
-reductase, like the enoyl reductase of the fatty acid elongating system, catalyzes the reduction of a double bond that is
,
to a carbonyl group. The discovery that the tsc13
mutants are deficient in VLCFA synthesis raised the possibility that
Tsc13p catalyzes the last step in each cycle of elongation, reduction of the trans-2,3-enoyl-CoA intermediate (Fig. 1).
|
The tsc13 mutant accumulates LCBs as well as ceramides
that have fatty acids with chain lengths of less than 26 carbons.
In contrast to wild-type cells, the elo2
and
elo3
mutant cells accumulated high levels of LCBs (Fig.
4 and reference 37). The
tsc13 mutant also accumulated free LCBs, and this phenotype was even more severe in tsc13-1 elo2
and tsc13-1
elo3
double mutants than in the single mutants (Fig. 4). The
accumulated LCBs, primarily phytosphingosine but also
dihydrosphingosine and small amounts of 3-ketosphinganine, are normal
intermediates in the LCB biosynthetic pathway. Thus, the mutant
phenotype may reflect reduced partitioning of the LCBs into ceramides
and sphingolipids because of a defect in VLCFA synthesis in the
mutants.
|
,
elo3
, and tsc13-1 mutant cells displayed
reduced TLC mobilities indicative of increased hydrophilicity in
comparison to the C-ceramide (containing phytosphingosine and
-OH-C26) present in wild-type cells (Fig. 5a). The accumulation of the relatively
hydrophilic ceramides was more severe in the tsc13-1 elo2
and tsc13-1 elo3
double mutants than in the single
mutants. The mobility of these ceramide species suggested that they
were likely to be hydroxylated on the
-carbon of the fatty acid and
to contain fatty acids of chain lengths shorter than C26.
To test this hypothesis, we disrupted the SCS7 gene encoding
the enzyme required for the
-hydroxylation of the VLCFA (20,
34) and compared the ceramides present in the single and double
mutants. The increased mobility of the ceramides in scs7
elo2
and scs7
elo3
double mutants confirmed
that Scs7p (Figure 5b) hydroxylates the ceramides in the mutants.
|
elo2
and
scs7
elo3
double mutants also displayed altered
ceramide mobilities consistent with increased hydrophilicity. To
investigate whether this was indeed due to shorter chain lengths of the
fatty acids, the ceramides were purified from the TLC plates and
hydrolyzed, and the methyl esters of the liberated fatty acids were
analyzed by GC-mass spectrometry. As shown in Figure 5c, the mutant
strains accumulated ceramides containing fatty acids with less than 26 carbons. The net ceramide levels do not appear to be appreciably lower
than in wild-type cells (Fig. 5a). However, while the
C24-containing ceramides are inositolphosphorylated, the
resulting IPCs are not mannosylated (37). Furthermore, the
hydrophilic ceramides containing fatty acids with chain lengths shorter
than C24 apparently are not inositolphosphorylated since
hydrophilic IPCs do not accumulate in the elongase mutants (data not
shown). Taken together, these data suggest that the accumulation of LCB
in the elo2, elo3, and tsc13 mutants
may reflect, at least in part, reduced incorporation of the LCBs into
the mature sphingolipids, presumably due to impaired availability of VLCFAs.
The tsc13 mutant has a defect in VLCFA synthesis.
The fatty acid composition of the mutant cells confirmed a deficiency
in VLCFA synthesis. The tsc13 mutant cells had greatly (~25%) reduced levels of 26:0 (Fig.
6a), which is the predominant species
found in wild-type cells, and an approximate fourfold increase in the
24:0 intermediate species. By comparison, the elo3
mutant
lacked 26:0 and accumulated high levels of C22 and C20 intermediates, while the elo2
mutant was
deficient in the synthesis of all VLCFA species. The tsc13,
elo2
, and elo3
mutants also exhibited
striking differences from wild type in their hydroxy fatty acid
profiles (Fig. 6b). In particular, the three mutants accumulated high
levels of OH-16:0, and the elo2
mutant also accumulated
significant levels of OH-18:0. OH-C16 and
OH-C18 fatty acids were not detected in wild-type cells.
The three mutants also displayed high levels of OH-24:0, a minor
species in the wild type, and reduced levels of OH-26:0 (particularly
elo3), which is the most abundant hydroxylated fatty acid in
the wild type. As indicated previously, the elo3 mutant
accumulated high levels of 20:0 and 22:0, which was not found in either
the tsc13 or elo2 mutant.
|
The tsc13 mutant has reduced fatty acid elongation
activity.
The TSC13 gene, unlike the ELO2
and ELO3 genes, is essential for viability, and there are no
TSC13 homologous genes in the S. cerevisiae
genome. Elo2p and Elo3p have partially redundant functions and are
believed to participate in the same step of the elongation cycle, with
preferences for acyl-CoA substrates of different chain lengths
(37, 59). However, Tsc13p is likely to be required for
catalyzing a step in each cycle of fatty acid elongation for acyl-CoA
substrates of all chain lengths. To address which step of elongation
might be affected by the tsc13 mutation, microsomes were
prepared from the tsc13 mutant cells and assayed for
elongase activity in vitro. For these experiments, the incorporation of
[2-14C]malonyl-CoA into elongated acyl-CoA products was
measured. The first step of the elongation cycle is the condensation of
malonyl-CoA with an acyl-CoA (e.g., palmitoyl-CoA) to form a
3-ketoacyl-CoA intermediate (Fig. 1). Omitting pyridine nucleotide from
the assay mix prevents the reduction of the 3-ketoacyl-CoA
intermediate, thereby allowing the first step of elongation
(condensation) to be measured. The condensation activity measured in
wild-type or tsc13-1 microsomes was very similar when
palmitoyl-CoA (or eicosanoyl-CoA) was used as a substrate (Fig.
7a). However, the total elongation activity measured using microsomes from the tsc13 mutant
cells was about 50% of that in wild-type microsomes for each of the acyl-CoA substrates tested (Fig. 7a). These results indicate that Tsc13p catalyzes a step in elongation subsequent to the condensation step.
|
-reductase, Tsc13p may directly
catalyze the reduction of the enoyl intermediate in each cycle of fatty
acid elongation.
Tsc13p coimmunoprecipitates with Elo2p and Elo3p.
The enzymes
responsible for fatty acid elongation have not yet been purified, and
virtually nothing is known about their molecular organization. For
example, it is not known whether they associate into a complex that
processively elongates fatty acids, or whether the acyl-CoA
intermediates diffuse from one membrane-associated elongating enzyme to
the next. To address whether Tsc13p associates with Elo2p and Elo3p, we
attempted protein coimmunoprecipitation. The plasmid carrying the
Myc-tagged TSC13 allele (MYC-TSC13-426) was transformed into
TDY2058 (Table 1) independently or in combination with a plasmid
carrying either HA-tagged Elo3p or HA-tagged Elo2p. Tsc13p, Elo2p, and
Elo3p (as their Myc- or HA-tagged versions, respectively) were all
found to display detergent solubilization properties indicating that
they are tightly associated integral membrane proteins (data not
shown). Antibodies to the Myc epitope coimmunoprecipitated Elo2p-HA or
Elo3p-HA along with Tsc13p-Myc, and vice versa (Fig. 8), from
solubilized microsomal preparations. These data suggest that Tsc13p
forms complexes with Elo2p and with Elo3p. It is not yet known whether
Elo2p and Elo3p coexist in the same Tsc13p-containing complexes.
Although it appears that Elo3p is more abundant than Elo2p (Fig.
8, lower panel, compare lanes 1 and 2),
the tagged proteins are being expressed by the ADH1 promoter
on plasmids. Furthermore, the strain (TDY2058) harboring the tagged
proteins lacks the wild-type ELO3 gene but has the wild-type
ELO2 gene, and the level of either tagged protein is reduced
when the corresponding endogenous wild-type protein is present (data
not shown).
|
Tsc13p localizes in the ER and is enriched at sites of
vacuole-nuclear envelope interaction.
Based on cell fractionation
of the epitope-tagged proteins, Elo2p, Elo3p (reference
14 and this study), and Tsc13p are present in the
microsomal membrane fraction, suggesting localization to the ER. To
analyze Tsc13p subcellular localization in greater detail, Tsc13p was
C-terminally tagged with GFP by chromosomal fusion. The localization of
Tsc13p-GFP, demonstrated to be a functional protein, revealed a
perinuclear and peripheral staining consistent with association with
the ER (Fig. 9A). A similar pattern of
staining was observed in cells expressing a chromosomal Elo3p-GFP
fusion (Fig. 9B, 2a and c). Elo2p-GFP, expressed from an episomal
plasmid under control of the GAL1 promoter, showed a
staining pattern indistinguishable from that of Elo3p-GFP (Fig. 9B, 3a
and c), and Opi3p-GFP, which was used as a control for the ER
(24) (Fig. 9B, 4a and c). Interestingly, however, in
addition to the typical nuclear rim-ER staining exhibited by Elo2p,
Elo3p, or Opi3p, Tsc13p-GFP was highly enriched in structures
reminiscent of the recently described nuclear-vacuolar junctions
(39) that are contact sites between the nucleus and the
vacuole (Fig. 9A). The intensity of the Tsc13p-GFP signal and
enrichment of Tsc13p to the sites of nuclear-vacuolar interaction
increased during growth on complete medium. Furthermore, vesicles that
contain Tsc13p-GFP in the membrane appeared closely associated to, or
even enclosed by, FM4-64-labeled vacuolar membrane structures (Fig.
9A). These structures appeared more frequently as cells entered
stationary phase.
|
|
Tsc13p-GFP localization is independent of Elo2p and Elo3p. To further determine whether Tsc13p localization is dependent on the presence of either Elo2p or Elo3p, Tsc13p-GFP distribution was analyzed in elo2 or elo3 mutants, respectively (elo2 elo3 double mutants are nonviable). Labeling of cells with FM4-64 revealed that the vacuolar morphology was drastically altered in elo2 and elo3 mutants and displayed a multilobed structure, reminiscent of vac8 mutants (47, 66) (Fig. 10B). Despite the high fragmentation of vacuoles into smaller vesicles, the polarity of Tsc13p localization was still maintained and the protein was still present at nuclear-vacuolar junctions. No alteration of the Tsc13p distribution was observed in these mutants, compared to wild type, suggesting that neither Elo2p is Elo3p are required for polarized Tsc13p localization at the nuclear-vacuolar junction.
Expression of Tsc13p-GFP does not result in the formation of
karmellae.
Some ER-resident proteins, e.g., Hmg1p
(hydroxymethylglutaryl-CoA reductase), when overexpressed lead to the
formation of karmellae, which are multiple stacks of ER membrane,
highly enriched in these proteins (27, 40, 67). As a
consequence, karmellae induced by Hmg1p-GFP appear as very bright
structures on the surface of the nucleus, at regions located opposite
the vacuole (27). As shown in Fig.
11A, the localization of karmellae,
albeit similar in appearance on the nuclear surface, is clearly
different from the localization pattern of Tsc13p-GFP in the
nuclear-vacuolar contact sites. In addition, ER membranes labeled with
DiOC6 (27) in strains expressing Tsc13p-GFP
appeared indistinguishable from wild type, demonstrating that GFP
tagging of Tsc13p does not result in the formation of karmellae. This
was further confirmed by electron microscopy demonstrating lack of any
membrane proliferations in Tsc13p-GFP-expressing strains (data not
shown).
|
The polarized localization of Tsc13p-GFP depends on the presence of vacuoles. Depending on growth phase, in the presence of nonfermentable carbon sources, or in elo2 and elo3 mutants, yeast vacuoles may split up into multiple smaller vesicles. Under these conditions, Tsc13p-GFP was consistently present in nuclear-vacuolar junctions. To test whether intact vacuoles are required to maintain this polarity, we have analyzed Tsc13p-GFP distribution in pep3 mutants which contain only vestigial nonacidic vacuoles (41, 42). As shown in Fig. 11B, the polarity of Tsc13p-GFP localization on the nuclear surface is lost in pep3 mutants but still appears somewhat clustered.
Taken together, the localization data suggest that Tsc13p is a component of the ER and that its enrichment at the nuclear-vacuolar interface is dependent on the presence of vacuolar membranes. The factors establishing this polarized localization pattern are still obscure but may be dispensable for Tsc13p to fulfill its essential function.| |
DISCUSSION |
|---|
|
|
|---|
VLCFAs are essential cellular components that are predominantly present in sphingolipids, the lipid moiety of GPI anchors, and to some extent in a novel PtdIns species recently identified in nuclear membrane extracts (51). Based on nuclear membrane phenotypes associated with reduced synthesis of C26 in conditional acc1 mutants, a structural role for VLCFA in stabilizing the highly curved nuclear membrane at the nuclear pore complex was postulated (48, 51). The importance of VLCFAs for cell viability is further demonstrated by the fact that mutants unable to synthesize sphingolipids produce novel PtdIns species that contain C26 in the sn-2 position (30). Studies to determine the structures and organization of the enzymes responsible for VLCFA synthesis have only recently become possible. Multiple elongating systems within the same organism are apparently responsible for elongating acyl-CoA substrates with different chain lengths and degrees of unsaturation. The identification in S. cerevisiae of three structurally and functionally related elongase proteins, Elo1p, Elo2p, and Elo3p, that display different chain length preferences are consistent with this suggestion (37, 59). Since they control the abundance of fatty acids with different chain lengths, it seems likely that these proteins participate in the condensation step of elongation. However, the yeast Elo proteins have no homology to any of the condensing enzymes that have been characterized so far at the molecular level. For example, several genes encoding putative condensing enzymes of fatty acid elongation have been cloned from plants and have been demonstrated to stimulate VLCFA synthesis in heterologous expression systems (29, 32, 33). Interestingly, there are no homologs of these plant genes in S. cerevisiae, but there are homologs of the ELO genes in plants.
The characterization of mammalian homologs of the ELO genes has recently been undertaken (61). One mammalian homolog (Ssc1) was found to complement the sphingolipid deficiency of the elo3 mutant, and another (Cig30) reversed the phenotype of the elo2 mutant. Furthermore, Ssc1 mRNA levels were reduced in the brains of myelin-deficient mice that are known to have low fatty acid elongation activity.
In addition to the condensation reaction, a reduction step, a
subsequent dehydration, and a second reduction are required for fatty
acid chain elongation. The studies presented here demonstrate that the
nonredundant TSC13 gene encodes a protein required for the
enoyl reductase activity of fatty acid elongation. Based on the
homology of Tsc13p to steroid-5-
-reductase, it is likely that Tsc13p
is the enoyl reductase enzyme per se. Tsc13p is a member of a family of
proteins that have been conserved from yeast to mammals. Substitution
of the glutamine with lysine at residue 81 of Tsc13p is responsible for
the ts phenotype conferred by the tsc13-1 mutant allele.
This residue is conserved in all Tsc13p homologs in the database. The
rat TSC13 homolog, SC2, was initially identified
as a gene that is highly expressed in brain, an organ where VLCFA
synthesis is known to occur at high rates.
For the synthesis of long-chain fatty acids up to C16, similar reactions are catalyzed by the multifunctional cytosolic FAS complex. Interestingly, none of the FAS domains has any homology to Elo2p, Elo3p, or Tsc13p. Furthermore, tsc13-1 mutants are not hypersensitive to diazaborin, a drug that inhibits bacterial enoyl-acyl carrier protein reductase (4), suggesting different reaction mechanisms for these enzymes.
The incorporation of VLCFA into sphingolipid is catalyzed by ceramide
synthase, which has not been identified yet. In wild-type cells, VLCFAs
are hydroxylated on C-2 by Scs7p after they are incorporated into
ceramide (16, 20). Fatty acids with chain lengths shorter
than C26 are not normally incorporated into ceramide and
are thus not hydroxylated in wild-type cells. However, in mutants with
VLCFA synthesis defects, fatty acids shorter than C26 are
incorporated into ceramide and are thus subject to hydroxylation by
Scs7p. It is interesting that the elo2
and
tsc13-1 mutant cells contained similar levels of the
hydroxylated C26 fatty acid as did wild-type cells, whereas
the overall content of C26 was reduced. Thus, ceramide
synthase appears to have a strong preference for C26 fatty
acids but is also able to modify the fatty acids with chain lengths of
less than C26 that accumulate in elo2 and tsc13-1 mutants. Since in wild-type cells none of the
intermediates of the elongation reaction appear in hydroxylated form in
ceramides, we suggest a metabolic channeling mechanism for VLCFA
synthesis that would require a concerted action of the elongase
complex, including Elo2, Elo3p, and Tsc13p, prior to incorporation of
VLCFA into sphingolipid by ceramide synthase. Alternatively, synthesis of the C16- to C24-containing ceramides in the
mutants could arise from the reversed activity of the ceramidase enzyme
encoded by YPC1 (condensation of LCBs with free fatty acids
31) acids rather than from ceramide synthase) (Fig.
1). The reverse ceramidase reaction may be driven by the high levels of
LCBs in the elongase mutants.
Ceramides in yeast are subject to inositolphosphorylation (an essential process) and subsequent mannosylation, which represents a nonessential modification to this class of lipids. It is interesting that the enzymes responsible for mannosylation of the IPC require a ceramide with a C26 fatty acid and that C24 ceramides accumulating in elongation mutants are not mannosylated. The chain length of the fatty acid is apparently also important for discrimination of IPC from PtdIns, since in slc1 mutants that incorporate C26 fatty acids into PtdIns this phospholipid becomes mannosylated. Thus, the availability of particular VLCFA species in a lipid appears to determine downstream lipid modification processes. Interestingly, recent studies using fatty acid elongation mutants defective in elo1 suggest that the availability of fatty acids with certain chain lengths could also be an important determinant of phospholipid composition (50). The molecular mechanisms involved, however, remain to be determined.
The unique localization of Tsc13p to a specific domain within the ER membrane at the nuclear-vacuolar interface raises many questions. It will be interesting to determine whether this domain of the ER membrane is the site where VLCFA synthesis occurs. It is possible that other enzymes required for sphingolipid synthesis, for example, the subunits of serine palmitoyltransferase or ceramide synthase, reside in this domain. Based on the experiments described here, this domain at the nuclear-vacuolar interface is not required for the function of Tsc13p, but its formation requires interaction with vacuolar membranes. Only recently, in studies on the localization of the vacuolar membrane protein Vac8p, a similar asymmetric protein distribution was observed at sites of vacuolar-vacuolar (38, 66) and vacuolar-nuclear envelope (47) interactions. Polarity of Vac8p to so-called nucleus-vacuole junctions requires the presence of Nvj1p in the nuclear envelope (39). Similarly, polarized localization of Nvj1p in the nuclear envelope depends on the presence of Vac8p. Whether Tsc13p requires Nvj1p or Vac8p for localization to sites of nucleus-vacuole interaction remains to be determined. However, localization of neither Nvj1p, Vac8p, nor Tsc13p to this domain is essential for viability, since both nvj1 or vac8 mutants and pep3 mutants deficient in vacuolar structures are viable. Furthermore, enrichment of Tsc13p to this domain is not dependent on C26 VLCFA since its localization is not altered in the elo mutants.
What could be the physiological role of the polarized localization of Tsc13p, or of the fatty acid elongation system, to sites of nuclear-vacuolar interaction? Due to the extended hydrophobic chain of VLCFAs, it might be necessary to provide a protein complex to accommodate these fatty acids in the membrane. Biochemical data as discussed above have already suggested a metabolic channeling mechanism for VLCFA synthesis. The role of vacuoles in this process is not clear. However, the appearance of vesicles highly enriched in Tsc13p that are budding off the nuclear membrane into the lumen of the vacuole when cells enter stationary phase indicates that a site of nuclear-vacuolar interaction may be a preferred site of nuclear envelope recycling. Thus, the striking nuclear membrane phenotype in mtr7 mutants defective in ACC, and thus in fatty acid chain elongation (48, 49), may be a consequence of perturbed nuclear membrane recycling to the vacuole.
VLCFAs are essential components of sphingolipids and, due to the
extended hydrophobic chain, represent a major structural determinant
for the membrane harboring these lipids. In mammalian cells,
sphingolipids and cholesterol may assemble to form lipid rafts, which
are characterized as detergent-insoluble membrane fractions. Very
recently, lipid rafts have also been identified in yeast, and evidence
suggests that certain secretory proteins, e.g., Pma1p and Gas1p,
associate with rafts at the level of the ER (1). The basis
for the formation of sphingolipid-cholesterol-enriched (detergent-insoluble) domains is not understood, but perhaps these membrane domains are synthesized in the ER membrane as a result of the
enrichment of a specific class of lipid biosynthetic enzymes within a
domain of the membrane. Thus, localized synthesis of VLCFAs and their
incorporation into sphingolipids may lead to sequestering sterols to
form detergent-insoluble membrane domains at specific sites
the
nuclear-vacuolar interface of the ER. Furthermore, the possibility that
a specific class of secretory vesicles buds off from this domain of the
ER is raised.
| |
ACKNOWLEDGMENTS |
|---|
We thank E. Schweizer, A. Tartakoff, R. Wright, A. Jandrositz, E. Jones, J. Hegemann, H. Klein, and B. Winsor for providing yeast strains and plasmids, A. Kauschmann (BASF) for the gift of Soraphen A, G. Högenauer for the gift of diazaborin, and G. Gogg for excellent technical assistance. We also thank D. Goldfarb for helpful discussions about nuclear-vacuolar junctions and I. Kaizer and M. Veenhuis for electron microscopy analysis.
This work was supported by NIH grant GM51891 and NSF grant G171FL to T.D., NIH GM45768 to C.E.M. and the Austrian Science Fund, FWF (project F706), Oesterreichische Nationalbank (project P7273), BIO4-CT97-2294 (EUROFAN II essential genes) of the European Union, and the Austrian Ministry of Education, Science and Culture (EUROFAN II supplement project; AUSTROFAN) to S.D.K.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Biochemistry, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814. Phone: (301) 295-3592. Fax: (301) 295-3512. E-mail: tdunn{at}usuhs.mil.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Bagnat, M.,
S. Keranen,
A. Shevchenko, and K. Simons.
2000.
Lipid rafts function in biosynthetic delivery of proteins to the cell surface in yeast.
Proc. Natl. Acad. Sci. USA
97:3254-3259 |
| 2. |
Beeler, T.,
D. Bacikova,
K. Gable,
L. Hopkins,
C. Johnson,
H. Slife, and T. Dunn.
1998.
The Saccharomyces cerevisiae TSC10/YBR265w gene encoding 3-ketosphinganine reductase is identified in a screen for temperature-sensitive suppressors of the Ca2+-sensitive csg2 mutant.
J. Biol. Chem.
273:30688-30694 |
| 3. | Beeler, T. J., D. Fu, J. Rivera, E. Monaghan, K. Gable, and T. M. Dunn. 1997. SUR1 (CSG1/BCL21), a gene necessary for growth of Saccharomyces cerevisiae in the presence of high Ca2+ concentrations at 37°C, is required for mannosylation of inositolphosphorylceramide. Mol. Gen. Genet. 255:570-579[CrossRef][Medline]. |
| 4. |
Bergler, H.,
P. Wallner,
A. Ebeling,
B. Leitinger,
S. Fuchsbichler,
H. Aschauer,
G. Kollenz,
G. Hogenauer, and F. Turnowsky.
1994.
Protein EnvM is the NADH-dependent enoyl-ACP reductase (FabI) of Escherichia coli.
J. Biol. Chem.
269:5493-5496 |
| 5. | Bernert, J. T., Jr., J. M. Bourre, N. A. Baumann, and H. Sprecher. 1979. The activity of partial reactions in the chain elongation of palmitoyl-CoA and stearoyl-CoA by mouse brain microsomes. J. Neurochem. 32:85-90[CrossRef][Medline]. |
| 6. |
Choi, J. Y., and C. E. Martin.
1999.
The Saccharomyces cerevisiae FAT1 gene encodes an acyl-CoA synthetase that is required for maintenance of very long chain fatty acid levels.
J. Biol. Chem.
274:4671-4683 |
| 7. | Cinti, D. L., L. Cook, M. N. Nagi, and S. J. Suneja. 1992. The fatty acid chain elongation system of mammalian endoplasmic reticulum. Prog. Lipid Res. 31:1-51[CrossRef][Medline]. |
| 8. | Coghlan, A., and K. H. Wolfe. 2000. Relationship of codon bias to mRNA concentration and protein length in Saccharomyces cerevisiae. Yeast 16:1131-1145[CrossRef][Medline]. |
| 9. |
Costanzo, M. C.,
J. D. Hogan,
M. E. Cusick,
B. P. Davis,
A. M. Fancher,
P. E. Hodges,
P. Kondu,
C. Lengieza,
J. E. Lew-Smith,
C. Lingner,
K. J. Roberg-Perez,
M. Tillberg,
J. E. Brooks, and J. I. Garrels.
2000.
The yeast proteome database (YPD) and Caenorhabditis elegans proteome database (WormPD): comprehensive resources for the organization and comparison of model organism protein information.
Nucleic Acids Res.
28:73-76 |
| 10. | David, C., M. Solimena, and P. De Camilli. 1994. Autoimmunity in stiff-man syndrome with breast cancer is targeted to the C-terminal region of human amphiphysin, a protein similar to the yeast proteins, Rvs167 and Rvs161. FEBS Lett. 351:73-79[CrossRef][Medline]. |
| 11. |
David, D.,
S. Sundarababu, and J. E. Gerst.
1998.
Involvement of long chain fatty acid elongation in the trafficking of secretory vesicles in yeast.
J. Cell Biol.
143:1167-1182 |
| 12. | Desfarges, L., P. Durrens, H. Juguelin, C. Cassagne, M. Bonneu, and M. Aigle. 1993. Yeast mutants affected in viability upon starvation have a modified phospholipid composition. Yeast 9:267-277[CrossRef][Medline]. |
| 13. | Dickson, R. C. 1998. Sphingolipid functions in Saccharomyces cerevisiae: comparison to mammals. Annu. Rev. Biochem. 67:27-48[CrossRef][Medline]. |
| 14. |
Dittrich, F.,
D. Zajonc,
K. Huhne,
U. Hoja,
A. Ekici,
E. Greiner,
H. Klein,
J. Hofmann,
J. J. Bessoule,
P. Sperling, and E. Schweizer.
1998.
Fatty acid elongation in yeast biochemical characteristics of the enzyme system and isolation of elongation-defective mutants.
Eur. J. Biochem.
252:477-485[Medline].
|
| 15. | Dunn, T. M., K. Gable, E. Monaghan, and D. Bacikova. 2000. Selection of yeast mutants in sphingolipid metabolism. Methods Enzymol. 312:317-330 |